Skip to main content

Table 1 Baseline characteristics of phenprocoumon, composite low-dose DOAC (ld-DOAC) cohort and single ld-DOAC cohorts

From: Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data

 

Phenprocoumon

ld-DOAC

ld-Apixaban

ld-Dabigatran

ld-Edoxaban

ld-Rivaroxaban

n

20,179

21,724

10,997

1914

2255

6558

Baseline characteristics: mean (SD)

 Age

74.81 (10.11)

79.51 (9.67)

81.48 (8.70)

76.5 (10.36)

79.96 (9.19)

76.94 (10.34)

 Female persons (%)

41.70

49.77

53.19

43.78

53.48

44.50

 CCI

3.03 (2.08)

3.58 (2.15)

3.77 (2.14)

3.2 (2.1)

3.5 (2.18)

3.39 (2.13)

 CHA2DS2-VASc-Score (without gender)

3.7 (1.59)

4.21 (1.56)

4.41 (1.49)

4.06 (1.65)

4.05 (1.53)

3.98 (1.61)

 Prescriptions in addition to OAC

9.81 (5.28)

10.81 (5.55)

11.13 (5.55)

9.89 (5.18)

10.37 (5.46)

10.7 (5.63)

Comorbidities: Proportion of patients with … (%)

 Acute renal impairment

6.49

9.59

11.34

4.96

9.62

7.99

 Moderate chronic renal impairment

22.56

32.57

35.37

21.06

36.72

29.80

 Severe chronic renal impairment

6.00

6.44

8.07

1.57

7.36

4.82

 Renal impairment (total)

33.80

45.59

49.65

29.83

49.53

42.04

 Dementia

8.66

17.90

21.14

13.06

16.54

14.33

 Thrombosis

3.68

4.00

3.92

2.72

3.28

4.77

 Arterial hypertension

89.55

91.25

92.37

89.92

89.76

90.29

 Diabetes

36.58

39.97

40.27

35.32

39.96

40.85

 Smoker

8.22

7.14

6.27

8.15

6.16

8.65

 Alcohol abuse

3.03

3.42

3.19

3.19

3.41

3.86

 Myocardial infarction

8.80

11.84

10.78

13.48

7.80

14.53

 Stroke

4.20

5.61

6.29

7.84

3.99

4.36

 Atherosclerosis

19.68

21.69

22.23

20.38

21.64

21.20

 Cancer

21.50

24.73

25.84

21.79

26.03

23.28

 Liver disease

18.48

18.11

17.77

17.29

20.22

18.19

 Cachexia

0.69

1.95

2.31

0.84

1.86

1.69

 Adiposity

28.09

24.36

23.19

22.15

23.73

27.19

 Orthopaedic implant

3.49

8.83

9.04

5.22

11.49

8.63

Comedication: Proportion of patients with … (%)

 Antihypertensive medication

7.45

7.92

8.25

6.74

9.00

7.35

 Heparin

26.77

10.13

9.97

9.67

10.38

10.46

 Diuretics

54.96

59.63

64.05

48.69

57.34

56.19

 Antiarrhythmic med.

87.76

86.97

87.59

85.16

85.68

86.92

 NSAIDs

32.88

32.79

31.45

34.74

30.95

35.10

 Antiplatelet therapy

26.05

36.83

36.72

36.31

30.64

39.28

 Lipid lowering medication

47.88

48.15

47.48

54.08

45.19

48.57

 Anti-ulcer therapy

47.10

53.65

55.26

49.01

49.36

53.80

 Cardiac glycosides

11.44

9.91

10.76

7.94

8.65

9.50

 Oral corticosteroids

12.74

14.51

14.45

14.37

14.01

14.84

 Antipsychotic medication

4.39

9.26

10.65

7.68

8.38

7.69

Inpatient diagnosis before index date … (%)

 Thromboembolic event

5.80

11.91

14.28

20.79

7.14

6.98

 Bleeding

2.45

3.05

3.58

3.08

2.08

2.47

Outpatient diagnosis before index date … (%)

 Thromboembolic event

10.32

13.97

15.26

19.64

11.13

11.13

 Bleeding (no blood transfusion)

1.58

2.09

2.38

1.99

1.95

1.69